Revelation Biosciences Inc (REVBU) Financials

$0.29

$0.00 (0.00%)

As on 20-Jan-2023 09:30EDT

Market cap

$-- Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Operating Expenses	10.01	3.09	--	--	--	--
Operating Profit (EBIT)	-10.01	-3.09	--	--	--	--
Other Income	--	--	--	--	--	--
Profit before Tax	-9.00	-2.13	--	--	--	--
Provision for Tax	--	--	--	--	--	--
Profit after Tax (Net Income)	-9.00	-2.13	--	--	--	--
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	--	--

Liabilities ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Shareholder's Funds	2.23	-7.82	3.41	--	--	--
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	2.91	--	--	--	--
Current Liabilities	4.37	5.49	1.21	--	--	--
Total Liabilities	10.98	48.39	4.62	--	--	--

Assets ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Non-Current Assets	0.10	48.30	--	--	--	--
Current Assets	6.51	0.08	4.62	--	--	--
Total Assets	10.98	0.57	4.62	--	--	--
Total Debt*	--	--	--	--	--	--
Net Current Assets	2.13	-0.23	3.41	--	--	--

Cashflow ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Cash From Operating Activities	--	-0.73	--	--	--	--
Cash Flow from Investing Activities	--	--	--	--	--	--
Cash from Financing Activities	--	8.00	--	--	--	--
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Adjusted EPS ($)	--	-10.75	-5.76	--	--	--
Cash EPS ($)	--	--	-5.72	--	--	--
Adjusted Book Value ($)	--	--	-21.15	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	--	-1.96	--	--	--
Free Cash Flow per Share ($)	--	--	-1.96	--	--	--

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
ROCE (%)	--	--	96.60	--	--	--
ROE (%)	--	--	96.60	--	--	--
ROA (%)	--	-94.41	-8.04	--	--	--
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	--	--	--	--	--	--
Net Profit Growth (%)	--	--	--	--	--	--
EPS Growth (%)	--	--	--	--	--	--
Book Value Growth (%)	--	-66.48	--	--	--	--

Valuation Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Price / Earnings	--	--	-2.03	--	--	--
Price / Book Value	--	--	-0.55	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	--	--	-2.03	--	--	--
Close Price ($)	10.80	0.32	11.67	--	--	--
High Price ($)	10.95	22.50	12.74	--	--	--
Low Price ($)	9.90	0.30	9.99	--	--	--
Market Cap ($ Cr)	--	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debt to Equity	--	--	--	--	--	--
Short term debt to equity ratio	--	--	-0.10	--	--	--
Current Ratio	--	1.49	0.02	--	--	--
Quick Ratio	--	1.49	--	--	--	--
Interest Coverage	--	-214.44	--	--	--	--

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.